Picture of BioSyntech logo

BSYI BioSyntech Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro Cap

Momentum

Relative Strength (%)
1m+13.25%
3m+8.18%
6m-99.93%
1yr-99.95%
Volume Change (%)
10d/3mn/a
Price vs... (%)
52w Highn/a
50d MAn/a
200d MAn/a

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capitaln/a
Return on Equityn/a
Operating Margin-6302.46%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Mar 201031st Mar 2011
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2010 / 2011

Blurred out image of BioSyntech EPS forecast chart

Profile Summary

BioSyntech, Inc. is a Canada-based biotechnology company. The Company is developing biotherapeutic thermogels for regenerative medicine (tissue repair) and therapeutic delivery. The Company's platform technology is a family of hydrogels called BST-Gel, some of which are liquid at low temperature and solid at human body temperature. These gels can be injected or applied to a specific local site and offers properties for the local repair of damaged tissue such as cartilage, bone and chronic wounds and provide the benefit of avoiding invasive surgery. The Company's lead, late-stage product, BST-CarGel is undergoing an international pivotal trial.

Directors

Last Annual
March 31st, 2009
Last Interim
December 31st, 2009
Incorporated
March 28th, 2006
Public Since
March 9th, 2022
No. of Employees
20
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
us flag iconPink Sheets on Nasdaq
Shares in Issue
116,441,283
Blurred out image of a map
Address
475 Armand-Frappier Blvd., LAVAL, H7V 4B3
Web
Phone
Auditors
KPMG LLP

BSYI Share Price Performance

Similar to BSYI

Picture of Acura Pharmaceuticals logo

Acura Pharmaceuticals

us flag iconPink Sheets on Nasdaq

Picture of Adhera Therapeutics logo

Adhera Therapeutics

us flag iconPink Sheets on Nasdaq

Picture of Advantis logo

Advantis

us flag iconPink Sheets on Nasdaq

Picture of Advaxis logo

Advaxis

us flag iconPink Sheets on Nasdaq

Picture of Adynxx logo

Adynxx

us flag iconPink Sheets on Nasdaq

FAQ

Or unlock with your email

Or unlock with your email